BAVA:VIE
Bavarian Nordic A/S
31,92 €
arrow_upward
+1,33%(+0,42) 1 d.
15. 10., 17:36:00 GMT+2 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre BAVA…
Otvoriť
31,60 €
Vysoká
31,92 €
Nízka
31,42 €
Trh. kap.
2,83 mld.
Priem. obj.
17,00
Objem
0,00
Max. za 52 týž.
32,47 €
Min. za 52 týž.
22,96 €
Počet zamestnancov
2 tis.
Otvoriť
31,60 €
Vysoká
31,92 €
Nízka
31,42 €
Trh. kap.
2,83 mld.
Priem. obj.
17,00
Objem
0,00
Max. za 52 týž.
32,47 €
Min. za 52 týž.
22,96 €
Počet zamestnancov
2 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
GlobeNewswire
·
pred 3 dňami
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Profil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Informácie o subjekte Bavarian Nordic A/S
Generálny riaditeľPaul Chaplin
Zamestnanci1,91 tis.
Dátum založenia1. 7. 1992
Hlavné sídlo-
Odvetvie-